News
(Reuters) -Novavax shares surged more than 17% before the bell on Monday, following the long-delayed approval of its COVID-19 ...
The U.S. Food and Drug Administration approved Novavax's COVIDd-19 vaccine with age restrictions after a six-week delay.
China on Sunday announced anti-dumping duties as high as 74.9% on imports of POM copolymers, a type of engineering plastic, ...
Gaithersburg’s Novavax has secured formal regulatory approval for its Covid vaccine. It's a major win, after the FDA delayed ...
In its Friday approval letter, the FDA didn’t explain the restrictions although they reflect skepticism about ...
This vaccine did previously have emergency approval by the FDA for use but can now be marketed in the U.S. for use, the ...
The vaccine will only be available to those at high risk from Covid—excluding those who may need it to protect a relative or ...
The U.S. Food and Drug Administration has granted limited approval to Novavax Inc.'s COVID-19 vaccine, restricting its use to ...
Covid shots are facing greater scrutiny from top federal health officials like RFK Jr. and the FDA's Marty Makary.
Investors reacted positively to the news, as the FDA’s approval not only enhances Novavax’s product offering but also solidifies its partnership with Sanofi, a key player in the vaccine market. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results